







This article discusses the use of splice-switching antisense oligonucleotides (ASOs) as a therapeutic strategy for diseases caused by aberrant RNA splicing. It focuses on enhanced splicing modulation achieved through NMA-modified antisense oligonucleotides, presenting research fi
Protuoso Biosciences, a California-based startup, has raised $9.5 million to advance its AI-designed multifunctional biologics platform. The company's MUXBODY technology enables engineering of multiple therapeutic modalities into a single molecule to target complex diseases from
longevity.technology·Tech by Flipboard·1d ago·5 min read






